- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03660657
Ozone Therapy in Refractory Ischemic Heart Disease. (O3Cardio)
Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Ischemic Heart Disease Refractory to Medical and Surgical Treatment: Randomized, Triple-blind Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the potential role of ozone therapy added to the standard management of patients with symptomatic refractory ischemic heart disease, III-IV functional class of the classification of the New York Heart Association (NYHA).
MAIN OBJECTIVES: 1) to evaluate clinical effect and quality of life related to health (HRQOL) of adding O3 to the standard treatment of these patients. 2) to estimate the additional costs of adding O3 to the standard treatment and to evaluate the cost-effectiveness ratio.
SECONDARY OBJECTIVES: 3) To evaluate the evolution of a) biochemical parameters; b) cardiovascular parameters; c) toxicity of O3. 4) Develop and evaluate the acceptability of a shared decision-making (SDM) tool between professionals and patients.
METHODOLOGY: Phase II-III clinical trial, randomized, triple-blind. Sample size: 18 patients.
TREATMENT: All patients will receive their standard treatment + 40 sessions of rectal insufflation:
- Ozone-Group (n = 9): O3/O2 concentration progressively increased from 10 to 30 µg/ml.
- Control-placebo-Group (n = 9): O3/O2 Concentration = 0 µg/ml (only O2).
Main Variables: 1) changes in the self-perceived quality of life (Minnesota scale). 2) Direct costs.
Secondary Variables: 1) biochemical parameters; 2) Cardiovascular parameters; 3) Side effects. 4) acceptability of patients to a shared decision-making (SDM) tool.
Length of treatment: 16 weeks.
Follow-up: 16 weeks after completion of O3.
Assessments: 1) Pre-O3 (basal), 2) pos-O3 (end of O3), 3) 4 months pos-O3.
Planned length of clinical trial: 36 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Las Palmas
-
Las Palmas De Gran Canaria, Las Palmas, Spain, 35019
- Dr. Negrin University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults with ischemic heart disease, Functional Class III-IV from the NYHA, with symptoms in spite of maximal conventional medical treatment and no suitable to further percutaneous or surgical procedures.
- It should be required clinical diagnosis by the Cardiology Department and confirmation by cardiac catheterization with coronary angiography.
- Ejection Fraction < 40%
- Patients who have signed and dated the study 's specific informed consent.
- Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit, and accept the use of appropriate contraceptive methods at least from the 14 days prior to the first dose of the study drug. up to 14 days after the last one.
Exclusion Criteria:
- Age < 18 or > 85 years old.
- Severe valve disease and/or dynamic left ventricular outflow tract obstruction.
- Pregnancy at the time of enrollment.
- Limited walking ability due to neurologic or orthopedic impairments of the legs
- Those who are incapable to fill in the scales used to measure the quality of life variables
- Cerebral vascular accident (CVA or Transient Ischemic Attack (TIA) within the previous 3 months or carotid stenosis > 80%.
- Acute myocardial infarction (AMI), Percutaneous coronary intervention (PCI) or transmyocardial laser revascularization (TMR or PMR) within the previous 3 months.
- Hemodynamically or clinically unstable patients.
- Severe or limiting pulmonary diseases.
- Specific liver enzymes [Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) > 5 times the upper limit of normal
- Increased creatinine > 3 times the upper limit of normal or Glomerular Filtration Rate (GFR) < 25 ml/min or who are on chronic renal dialysis.
- Severe peripheral vascular disease with rest pain or significant chronic wounds.
Uncontrolled cancer disease or severe active systemic infection or HIV.
- Life expectancy < 4 months
- Contraindication or disability for rectal ozone administration or to attend scheduled treatments.
- Known allergy to ozone.
- Patients who do not meet all the inclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ozone Group:
Standard treatment + Ozone therapy (O3/O2)
|
Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation.
O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
Other Names:
|
Placebo Comparator: Control Group:
Standard treatment + Oxygen (O2)
|
Control Group: Standard treatment + Oxygen (O2) by rectal insufflation.
O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Direct Hospital Cost (at the end of ozone therapy)
Time Frame: 16 weeks
|
The direct expenses incurred by the hospital in providing services (medication, tests, medical visits...) during the 16 weeks of ozone therapy (in euros).
|
16 weeks
|
Quality of Life (QoL) measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (at the end of ozone therapy)
Time Frame: 16 weeks
|
Self-reported evaluation of 21 physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life.
Each item is scored from 0 (no affected) to 5 (very much affected).
Total range from 0 (best) to 105 (worst)
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in quality of life by the "5-level, 5-dimension EuroQol" (EQ-5D-5L) questionnaire (at the end of ozone therapy)
Time Frame: 16 weeks
|
Self-reported evaluation of: a) 5 physical and emotional items scored in five levels, from 1 (best: I have no problem) to 5 (worst: I have extreme problem or I am unable to…) and b) additional self-assessment of health by a visual analogue scale (0 = worst health patient can imagine, 100 = best health patient can imagine)
|
16 weeks
|
Change from Baseline in Biochemical parameters of oxidative stress (at the end of ozone therapy)
Time Frame: 16 weeks
|
Serum levels of superoxide dismutase, glutathione, glutathione peroxidase and free radicals
|
16 weeks
|
Change from Baseline in Biochemical parameters of inflammation (at the end of ozone therapy)
Time Frame: 16 weeks
|
Serum levels of pro-inflammatory interleukins and TNFalpha
|
16 weeks
|
Incidence of severe adverse events in accordance with the definition of the Council for International Organizations of Medical Sciences (at the end of ozone therapy)
Time Frame: 16 weeks
|
Number of events that are fatal, life threatening, leading to or prolonging a stay in hospital, or resulting in severe disability
|
16 weeks
|
Change from Baseline in quality of life by the "Short Form 36-item health survey" (SF-36) questionnaire (at the end of ozone therapy)
Time Frame: 16 weeks
|
Self-reported evaluation of 36 items (0 = worst, 100 = best).
Final accumulated total range from 0 (worst) to 100 (best)
|
16 weeks
|
Change from Baseline in Montreal Cognitive Assessment (MOCA) questionnaire (at the end of ozone therapy)
Time Frame: 16 weeks
|
Assessment of 8 types of cognitive abilities by a total 30-point test (0 = worst, 30 = best)
|
16 weeks
|
Change from Baseline in Biochemical cardiac parameters (High sensitive troponin, pro-brain natriuretic peptide (proBNP)) (at the end of ozone therapy)
Time Frame: 16 weeks
|
Serum levels of high sensitive troponin and proBNP
|
16 weeks
|
Change from Baseline (by Echocardiograpy) of: left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) (at the end of ozone therapy)
Time Frame: 16 weeks
|
Measurement of volume (in ml) of LVEDV and LVESV.
|
16 weeks
|
Change from Baseline (by Echocardiograpy) of left ventricular ejection fraction (LVEF) (at the end of ozone therapy)
Time Frame: 16 weeks
|
Measurement (in percentage) of LVEF
|
16 weeks
|
Change from Baseline in Six-minute walk test (6MWT) (at the end of ozone therapy)
Time Frame: 16 weeks
|
Assessment of functional exercise capacity according to the walking distance covered over a time of 6 minutes (in meters)
|
16 weeks
|
Change from Baseline in cerebral blood flow by Transcranial doppler (at the end of ozone therapy)
Time Frame: 16 weeks
|
Doppler ultrasound evaluation of systolic and diastolic velocity in middle cerebral arteries (in cm/s)
|
16 weeks
|
Change from Baseline in Hyperspectral image of the supraciliary area (at the end of ozone therapy)
Time Frame: 16 weeks
|
Assessment of the percentage of reflectance for each wavelength
|
16 weeks
|
Change from Baseline in lower limb blood flow by Doppler ultrasound (at the end of ozone therapy)
Time Frame: 16 weeks
|
Doppler ultrasound evaluation of systolic and diastolic velocity in lower limbs (in cm/s)
|
16 weeks
|
Change from Baseline in Hyperspectral image of lower limbs (at the end of ozone therapy)
Time Frame: 16 weeks
|
Assessment of the percentage of reflectance for each wavelength
|
16 weeks
|
Quality of Life (QoL) measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (at 32 weeks)
Time Frame: 32 weeks
|
Self-reported evaluation of 21 physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life.
Each item is scored from 0 (no affected) to 5 (very much affected).
Total range from 0 (best) to 105 (worst)
|
32 weeks
|
Direct Hospital Cost (at 32 weeks)
Time Frame: 32 weeks
|
The direct expenses incurred by the hospital in providing services (medication, tests, medical visits...) during the 16 weeks of ozone therapy (in euros)
|
32 weeks
|
Change from Baseline in quality of life by the "5-level, 5-dimension EuroQol" (EQ-5D-5L) questionnaire (at 32 weeks)
Time Frame: 32 weeks
|
Self-reported evaluation of: a) 5 physical and emotional items scored in five levels, from 1 (best: I have no problem) to 5 (worst: I have extreme problem or I am unable to…) and b) additional self-assessment of health by a visual analogue scale (0 = worst health patient can imagine, 100 = best health patient can imagine)
|
32 weeks
|
Change from Baseline in quality of life by the "Short Form 36-item health survey" (SF-36) questionnaire (at 32 weeks)
Time Frame: 32 weeks
|
Self-reported evaluation of 36 items (0 = worst, 100 = best).
Final accumulated total range from 0 (worst) to 100 (best)
|
32 weeks
|
Change from Baseline in Montreal Cognitive Assessment (MOCA) questionnaire (at 32 weeks)
Time Frame: 32 weeks
|
Assessment of 8 types of cognitive abilities by a total 30-point test (0 = worst, 30 = best)
|
32 weeks
|
Change from Baseline in Biochemical cardiac parameters (High sensitive troponin, pro-brain natriuretic peptide (proBNP)) (at 32 weeks)
Time Frame: 32 weeks
|
Serum levels of high sensitive troponin and proBNP
|
32 weeks
|
Change from Baseline in Biochemical parameters of oxidative stress (at 32 weeks)
Time Frame: 32 weeks
|
Serum levels of superoxide dismutase, glutathione, glutathione peroxidase and free radicals
|
32 weeks
|
Change from Baseline in Biochemical parameters of inflammation (at 32 weeks)
Time Frame: 32 weeks
|
Serum levels of pro-inflammatory interleukins and TNFalpha
|
32 weeks
|
Change from Baseline (by Echocardiograpy) of: left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) (at 32 weeks)
Time Frame: 32 weeks
|
Measurement of volume (in ml) of LVEDV and LVESV.
|
32 weeks
|
Change from Baseline (by Echocardiograpy) of left ventricular ejection fraction (LVEF) (at 32 weeks)
Time Frame: 32 weeks
|
Measurement (in percentage) of LVEF
|
32 weeks
|
Change from Baseline in Six-minute walk test (6MWT) (at 32 weeks)
Time Frame: 32 weeks
|
Assessment of functional exercise capacity according to the walking distance covered over a time of 6 minutes (in meters)
|
32 weeks
|
Change from Baseline in cerebral blood flow by Transcranial doppler (at 32 weeks)
Time Frame: 32 weeks
|
Doppler ultrasound evaluation of systolic and diastolic velocity in middle cerebral arteries (in cm/s)
|
32 weeks
|
Change from Baseline in Hyperspectral image of the supraciliary area (at 32 weeks)
Time Frame: 32 weeks
|
Assessment of the percentage of reflectance for each wavelength
|
32 weeks
|
Change from Baseline in lower limb blood flow by Doppler ultrasound (at 32 weeks)
Time Frame: 32 weeks
|
Doppler ultrasound evaluation of systolic and diastolic velocity in lower limbs (in cm/s)
|
32 weeks
|
Change from Baseline in Hyperspectral image of lower limbs (at 32 weeks)
Time Frame: 32 weeks
|
Assessment of the percentage of reflectance for each wavelength
|
32 weeks
|
Incidence of severe adverse events in accordance with the definition of the Council for International Organizations of Medical Sciences (at 32 weeks)
Time Frame: 32 weeks
|
Number of events that are fatal, life threatening, leading to or prolonging a stay in hospital, or resulting in severe disability
|
32 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Bernardino Clavo, MD, PhD, Dr. Negrín University Hospital, Las Palmas, Spain
- Study Director: Pedro G Serrano-Aguilar, MD, PhD, Servicio de Evaluación. Servicio Canario de Salud. Spain
- Principal Investigator: Francisco Rodríguez-Esparragón, BSc, PhD, Dr. Negrín University Hospital, Las Palmas, Spain
- Principal Investigator: Bernardino Clavo, MD, PhD, Dr. Negrín University Hospital, Las Palmas, Spain
- Principal Investigator: Renata Linertová, PhD, Servicio de Evaluación. Servicio Canario de Salud. Spain
- Principal Investigator: Celestina Amador, MD, PhD, Dr. Negrín University Hospital, Las Palmas, Spain
- Principal Investigator: Norberto Santana-Rodríguez, MD, PhD, King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia
Publications and helpful links
General Publications
- Bocci V, Zanardi I, Travagli V. Ozone: a new therapeutic agent in vascular diseases. Am J Cardiovasc Drugs. 2011;11(2):73-82. doi: 10.2165/11539890-000000000-00000.
- Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front Chem. 2015 Feb 2;3:4. doi: 10.3389/fchem.2015.00004. eCollection 2015.
- Bocci VA, Zanardi I, Travagli V. Ozone acting on human blood yields a hormetic dose-response relationship. J Transl Med. 2011 May 17;9:66. doi: 10.1186/1479-5876-9-66.
- Buyuklu M, Kandemir FM, Set T, Bakirci EM, Degirmenci H, Hamur H, Topal E, Kucukler S, Turkmen K. Beneficial Effects of Ozone Therapy on Oxidative Stress, Cardiac Functions and Clinical Findings in Patients with Heart Failure Reduced Ejection Fraction. Cardiovasc Toxicol. 2017 Oct;17(4):426-433. doi: 10.1007/s12012-017-9400-8.
- Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. 2009 Jul;29(4):646-82. doi: 10.1002/med.20150.
- Clavo B, Perez JL, Lopez L, Suarez G, Lloret M, Rodriguez V, Macias D, Santana M, Morera J, Fiuza D, Robaina F, Gunderoth M. Effect of ozone therapy on muscle oxygenation. J Altern Complement Med. 2003 Apr;9(2):251-6. doi: 10.1089/10755530360623365.
- Clavo B, Catala L, Perez JL, Rodriguez V, Robaina F. Ozone Therapy on Cerebral Blood Flow: A Preliminary Report. Evid Based Complement Alternat Med. 2004 Dec;1(3):315-319. doi: 10.1093/ecam/neh039. Epub 2004 Oct 6.
- Clavo B, Eltobgy K, Caballero E, Abad C, Rodriguez-Esparragon F, Santana-Rodriguez N. Is There a Place for Ozone Therapy in Patients with Heart Failure? Cardiovasc Toxicol. 2017 Oct;17(4):496-497. doi: 10.1007/s12012-017-9423-1. No abstract available.
- Di Filippo C, Marfella R, Capodanno P, Ferraraccio F, Coppola L, Luongo M, Mascolo L, Luongo C, Capuano A, Rossi F, D'Amico M. Acute oxygen-ozone administration to rats protects the heart from ischemia reperfusion infarct. Inflamm Res. 2008 Oct;57(10):445-9. doi: 10.1007/s00011-008-7237-0.
- Giunta R, Coppola A, Luongo C, Sammartino A, Guastafierro S, Grassia A, Giunta L, Mascolo L, Tirelli A, Coppola L. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann Hematol. 2001 Dec;80(12):745-8. doi: 10.1007/s002770100377. Epub 2001 Oct 13.
- Martinez-Sanchez G, Delgado-Roche L, Diaz-Batista A, Perez-Davison G, Re L. Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease. Eur J Pharmacol. 2012 Sep 15;691(1-3):156-62. doi: 10.1016/j.ejphar.2012.07.010. Epub 2012 Jul 13.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- O3Cardio
- 2018-000201-24 (Other Identifier: Registro Español de Ensayos Clínicos (REec))
- PIFUN44/17 (Other Grant/Funding Number: Fundación Canaria de Investigación Sanitaria (FUNCANIS))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Heart Disease
-
Genzyme, a Sanofi CompanyTerminatedIschemic Heart Disease | Ischemic Cardiomyopathy | Ischemic Heart FailureBelgium, France, Germany, Italy, Switzerland, United Kingdom
-
Cardiocentro TicinoTerminatedChronic Ischemic Heart DiseaseSwitzerland
-
University of AlbertaRecruitingCoronary Artery Disease | Stable Ischemic Heart Disease | Beta-blocker TherapyCanada
-
Gerencia de Atención Primaria, MadridServicio Canario de Salud; Avedis Donabedian Research InstituteCompletedIschemic Heart Disease ChronicSpain
-
Michael SekelaCompletedChronic Ischemic Heart DiseaseUnited States
-
University of PecsCompleted
-
Rigshospitalet, DenmarkNot yet recruitingChronic Ischemic Heart DiseaseDenmark
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); Cardiovascular Cell Therapy...CompletedIschemic Cardiomyopathy | Left Ventricular Dysfunction | Angina | Chronic Ischemic Heart DiseaseUnited States
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUnknownHeart Failure | Angina | Chronic Ischemic Heart DiseaseChina
-
University of EdinburghUnknown
Clinical Trials on Ozone
-
University of RochesterNational Institute of Environmental Health Sciences (NIEHS); Exxon Mobil; Conservation...Completed
-
University of BaghdadCompletedImpacted Third Molar ToothIraq
-
Anhembi Morumbi UniversityActive, not recruitingBladder Pain Syndrome | Interstitial Cystitis, ChronicBrazil
-
Asmat BurhanNot yet recruitingDiabetic Foot Ulcer | Wound Heal | Ozone
-
Çanakkale Onsekiz Mart UniversityInonu UniversityCompleted
-
Sakarya UniversityUnknown
-
University of AarhusCompletedSubjective Discomfort | General Mucosal Irritation | Acute Changes in Respiratory Outcomes | Acute Changes in Cardiovascular Outcomes | Changes in BiomarkersDenmark
-
Ataturk UniversityCompleted
-
Martin W. CaseUniversity of North CarolinaRecruitingSymptoms and Signs | Lung Injury, Acute | Neutrophilia AcuteUnited States